Due to the current situation related to the coronavirus (COVID-19), study teams may experience delays in responding to signups and scheduling patients on StudyPages.A study team member will respond to you as soon as possible. More coronavirus resources and updates from UC Davis Veterinary Medicine can be found here.

Evaluating a new immunotherapy for advanced stage osteosarcoma and melanoma in dogs
Logo Image
"Help us study a new immunotherapy for cancer that has spread to the lungs of dogs with osteosarcoma or melanoma!"
Animal: Dogs
Age: None specified
Healthy Pets: No
Keywords: dog, canine, cancer, osteosarcoma, melanoma, advanced osteosarcoma, advanced melanoma, metastasis, lung, immunotherapy
Type: Immunotherapy
12 Participants
Background and purpose
The purpose of this study is to determine the maximum tolerated dose and efficacy of an immunotherapy protocol against metastatic osteosarcoma or melanoma growing within the lungs.
What happens in this study

It is important to note that inhalation treatments are being done by owners at home. If your dog is enrolled in the study, the following will be done:

  • We will provide you with a nebulizer set to facilitate training for delivery of inhaled IL-15 at home.
  • If your dog tolerates nebulization and meets inclusion criteria, you will have the option to enroll your dog. If you elect to enroll your dog, we will collect blood, get additional chest x-rays, and perform an ultrasound-guided fine needle aspirate of a lung mass while under sedation.
  • 3 days later, your pet will begin therapy with inhaled IL-15 twice daily for 14 days with the first session performed here at the VMTH.
  • Your dog will return once weekly during the first month for routine physical examinations and blood tests to ensure that they are tolerating the therapy well.
  • After completing the treatments, we will perform another fine needle aspirate and repeat blood tests. Chest x-rays will be repeated monthly. Sedation may be required to obtain chest x-rays.
Pet owner responsibilities

You will be responsible for tests to determine eligibility and keeping all scheduled appointments. Once your pet has been determined as eligible the study will cover the cost of the appointment including, physical exams, thoracic radiographs, bloodwork (CBC and Chemistry) the IL-15, and anything specifically related to the trial. In the event of an adverse event that is directly related to the trial, the study will cover up to $2000 for medical treatment. The owner will be responsible for filling out several reporting forms to let us know how your pet has been doing at home and returning the nebulizer and leftover supplies at the end of treatment.

Participation requirements

We are looking for dogs diagnosed with osteosarcoma or melanoma that has spread to the lungs.

To determine eligibility, your dog will need a physical exam, blood tests (including a complete blood count and serum chemistry panel), urinalysis, and chest x-rays. If the type of cancer is unknown, additional tests may be required in order to confirm the type of cancer before being allowed to take part in the study.

Benefits and risks of participating
Possible benefits to participating in this trial include response to therapy, decreased tumor burden, reduced clinical signs, or improved survival time.
The study will provide you with the nebulizer and supplies. If adverse events occur while participating in this trial, the study sponsors will cover up to $2000 for medical treatment at the UC Davis Veterinary Medical Teaching Hospital (the study cannot cover costs incurred at other clinics).
PDF Docs
Clinical Trial Informational Flyer
Study duration and period
The study may last up to 14 weeks.
Recruitment period
From Nov. 18, 2016
UC Davis Veterinary Medical Teaching Hospital
1 Garrod Drive
Small Animal Clinic - Oncology
Davis, CA 95616
Oncology Clinical Trial Coordinators

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview